treatment-naive patients with B-cell lymphoma
HBsAg positive at baseline
treated with rituximab-based immunochemotherapy
life expectancy of more than 3 months

NCT01768195_inc_T1
Condition
treatment
NCT01768195_inc_T2
Condition
B-cell lymphoma
NCT01768195_inc_T3
Negation
naive
NCT01768195_inc_T4
Condition
HBsAg positive
NCT01768195_inc_T5
Temporal
at baseline
NCT01768195_inc_T6
Qualifier
rituximab-based
NCT01768195_inc_T7
Drug
rituximab
NCT01768195_inc_T8
Procedure
immunochemotherapy
NCT01768195_inc_T9
Observation
life expectancy
NCT01768195_inc_T10
Value
more than 3 months